CL2014001103A1 - Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. - Google Patents
Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.Info
- Publication number
- CL2014001103A1 CL2014001103A1 CL2014001103A CL2014001103A CL2014001103A1 CL 2014001103 A1 CL2014001103 A1 CL 2014001103A1 CL 2014001103 A CL2014001103 A CL 2014001103A CL 2014001103 A CL2014001103 A CL 2014001103A CL 2014001103 A1 CL2014001103 A1 CL 2014001103A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- pyridone
- pharmaceutical
- inflammation
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555393P | 2011-11-03 | 2011-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001103A1 true CL2014001103A1 (es) | 2014-10-03 |
Family
ID=47146779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001103A CL2014001103A1 (es) | 2011-11-03 | 2014-04-29 | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. |
Country Status (34)
Country | Link |
---|---|
US (10) | US8716274B2 (es) |
EP (5) | EP3002284B1 (es) |
JP (5) | JP5976827B2 (es) |
KR (2) | KR20160003328A (es) |
CN (2) | CN104125959B (es) |
AR (2) | AR088641A1 (es) |
AU (5) | AU2012332365B2 (es) |
CA (1) | CA2853975C (es) |
CL (1) | CL2014001103A1 (es) |
CO (1) | CO6950472A2 (es) |
CR (1) | CR20140194A (es) |
CY (1) | CY1117097T1 (es) |
DK (2) | DK3002284T3 (es) |
EA (1) | EA023263B1 (es) |
ES (3) | ES2898938T3 (es) |
HK (1) | HK1201265A1 (es) |
HR (2) | HRP20151442T1 (es) |
HU (2) | HUE028019T2 (es) |
IL (1) | IL232060A (es) |
IN (1) | IN2014CN03250A (es) |
LT (1) | LT3002284T (es) |
MA (1) | MA35819B1 (es) |
MX (2) | MX361807B (es) |
PE (1) | PE20141586A1 (es) |
PL (3) | PL3002284T3 (es) |
PT (2) | PT3002284T (es) |
RS (2) | RS59016B1 (es) |
SG (1) | SG11201401992YA (es) |
SI (2) | SI3002284T1 (es) |
TR (1) | TR201909849T4 (es) |
TW (4) | TWI652270B (es) |
UA (1) | UA111756C2 (es) |
WO (1) | WO2013067274A1 (es) |
ZA (1) | ZA201804727B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012332368A1 (en) * | 2011-11-03 | 2014-05-22 | F. Hoffmann-La Roche Ag | Alkylated piperazine compounds as inhibitors of Btk activity |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
EP3016943B1 (en) * | 2013-07-03 | 2019-08-21 | F. Hoffmann-La Roche AG | Heteroaryl pyridone and aza-pyridone amide compounds |
JP2016535764A (ja) * | 2013-10-04 | 2016-11-17 | ビヨンド オンコロジー ファーマシューティカル エルエルシー | ブルトンのチロシンキナーゼの阻害剤 |
JP6275846B2 (ja) * | 2013-12-05 | 2018-02-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物 |
CN106922146B (zh) * | 2014-10-02 | 2020-05-26 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
JP6368043B2 (ja) | 2014-10-27 | 2018-08-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 三環式ラクタム化合物の製造法 |
CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
TWI724022B (zh) | 2015-09-02 | 2021-04-11 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 化合物 |
AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
KR20180110131A (ko) * | 2016-02-19 | 2018-10-08 | 노파르티스 아게 | 항바이러스제로서의 테트라시클릭 피리돈 화합물 |
EP3423059B1 (en) * | 2016-02-29 | 2022-03-23 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
JP6983813B2 (ja) * | 2016-04-28 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 2−ピラゾロ[1,5−a]ピラジン−2−イルピリド[1,2−a]ピリミジン−4−オンの調製のためのプロセス |
CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
AU2017368331A1 (en) | 2016-12-03 | 2019-06-13 | Acerta Pharma B.V. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
TWI673271B (zh) * | 2016-12-15 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 製備btk抑制劑之方法 |
TWI732083B (zh) | 2016-12-22 | 2021-07-01 | 大陸商貝達藥業股份有限公司 | 苯并咪唑衍生物、其藥物組合物及其應用 |
WO2018175863A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | Methods of treating autoimmune and inflammatory diseases |
CN107445981B (zh) * | 2017-08-25 | 2018-06-22 | 牡丹江医学院 | 一种用于防治宫颈炎的活性化合物 |
KR102613433B1 (ko) * | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
AU2018354972B2 (en) | 2017-10-27 | 2021-07-08 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of ribociclib and its salts |
US11100492B2 (en) * | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
US11702427B2 (en) | 2018-03-12 | 2023-07-18 | Arbutus Biopharma Corporation | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same |
EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
BR112021000964A2 (pt) | 2018-07-25 | 2021-04-20 | Novartis Ag | inibidores do inflamassoma de nlrp3 |
KR102328682B1 (ko) * | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
WO2020043321A1 (en) | 2018-08-31 | 2020-03-05 | Stichting Katholieke Universiteit | Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof |
KR20210077719A (ko) | 2018-10-15 | 2021-06-25 | 누릭스 테라퓨틱스 인코포레이티드 | 유비퀴틴 프로테오좀 경로를 통해 btk를 분해시키기 위한 이작용성 화합물 |
TW202033523A (zh) * | 2019-01-17 | 2020-09-16 | 美商愛彼特生物製藥股份有限公司 | 經取代的多環羧酸、其類似物及使用其之方法 |
KR20210119457A (ko) | 2019-01-22 | 2021-10-05 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법 |
EP3930717A1 (en) * | 2019-02-25 | 2022-01-05 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Inhibitor of btk and mutants thereof |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
US20220363689A1 (en) | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
WO2021091575A1 (en) * | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
IL293797A (en) | 2019-12-04 | 2022-08-01 | Nurix Therapeutics Inc | Bifunctional compounds for btk degradation via the ubiquitin proteosome pathway |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3171012A1 (en) * | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
WO2021173740A1 (en) | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
IL296990A (en) | 2020-04-03 | 2022-12-01 | Genentech Inc | Methods for the treatment of multiple sclerosis relapse using an inhibitor of proton tyrosine kinase |
WO2021254483A1 (zh) * | 2020-06-18 | 2021-12-23 | 上海华汇拓医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂及其制备方法 |
EP4192822A1 (en) * | 2020-08-04 | 2023-06-14 | F. Hoffmann-La Roche AG | Pyridinone compounds for the treatment of autoimmune disease |
KR20230051200A (ko) * | 2020-08-14 | 2023-04-17 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Btk 및 이의 돌연변이체의 억제제를 포함하는 투여 형태 조성물 |
CA3185469A1 (en) | 2020-08-14 | 2022-02-17 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
KR20230104125A (ko) | 2020-09-21 | 2023-07-07 | 허치슨 메디파르마 리미티드 | 헤테로아릴 헤테로사이클릭 화합물 및 이의 용도 |
WO2022094172A2 (en) | 2020-10-30 | 2022-05-05 | Newave Pharmaceutical Inc. | Inhibitors of btk |
JP2024503237A (ja) | 2020-12-20 | 2024-01-25 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Btk分解誘導薬 |
EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
WO2022233801A1 (en) | 2021-05-05 | 2022-11-10 | F. Hoffmann-La Roche Ag | Process for preparing btk inhibitors |
CN113603685A (zh) * | 2021-07-23 | 2021-11-05 | 都创(上海)医药开发有限公司 | Fenebrutinib化合物的晶型及其制备方法和用途 |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
WO2023137225A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Btk degrader |
WO2023143491A1 (zh) * | 2022-01-28 | 2023-08-03 | 和记黄埔医药(上海)有限公司 | 7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法 |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
CA2453113A1 (en) | 2001-07-12 | 2003-01-23 | Avecia Limited | Microencapsulated catalyst, methods of preparation and methods of use thereof |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US20100190688A1 (en) | 2004-07-12 | 2010-07-29 | Bin Chao | Tetrapeptide analogs |
WO2006053121A2 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
KR101357524B1 (ko) | 2005-03-10 | 2014-02-03 | 질레드 코네티컷 인코포레이티드 | 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법 |
EA032466B1 (ru) | 2005-10-07 | 2019-05-31 | Экселиксис, Инк. | Способы получения ингибиторов mek |
AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
ATE531263T1 (de) * | 2006-09-22 | 2011-11-15 | Pharmacyclics Inc | Hemmer der bruton-tyrosinkinase |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
WO2009053269A1 (en) * | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
NZ586916A (en) * | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
ES2554615T3 (es) | 2008-05-06 | 2015-12-22 | Gilead Connecticut, Inc. | Amidas sustituidas, método de preparación y utilización como inhibidores de Btk |
CA2728016C (en) * | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
PE20110164A1 (es) | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
CA2636807A1 (en) | 2008-07-04 | 2010-01-04 | Steven Splinter | Methods for obtaining cyclopamine |
ES2552681T3 (es) | 2008-07-15 | 2015-12-01 | F. Hoffmann-La Roche Ag | Nuevas fenil-imidazopiridinas y piridazinas |
US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
ES2513915T3 (es) * | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
US8765754B2 (en) * | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
HUE043522T2 (hu) * | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
ES2573716T3 (es) * | 2010-05-07 | 2016-06-09 | Gilead Connecticut, Inc. | Compuestos de piridona y aza-piridona y métodos de utilización |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
KR101837223B1 (ko) | 2010-09-01 | 2018-03-09 | 질레드 코네티컷 인코포레이티드 | 피리디논/피라지논, 그의 제조 방법 및 사용 방법 |
WO2012030990A1 (en) | 2010-09-01 | 2012-03-08 | Gilead Connecticut, Inc. | Pyridazinones, method of making, and method of use thereof |
CN103582637B (zh) | 2011-05-17 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | 酪氨酸激酶抑制剂 |
EP2744804B1 (en) | 2011-08-17 | 2017-05-17 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
JP5976826B2 (ja) * | 2011-11-03 | 2016-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Btk活性阻害剤としての8−フルオロフタラジン−1(2h)−オン化合物 |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
AU2012332368A1 (en) | 2011-11-03 | 2014-05-22 | F. Hoffmann-La Roche Ag | Alkylated piperazine compounds as inhibitors of Btk activity |
EP3016943B1 (en) * | 2013-07-03 | 2019-08-21 | F. Hoffmann-La Roche AG | Heteroaryl pyridone and aza-pyridone amide compounds |
JP6275846B2 (ja) * | 2013-12-05 | 2018-02-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物 |
EP3423059B1 (en) * | 2016-02-29 | 2022-03-23 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
-
2012
- 2012-02-11 UA UAA201405799A patent/UA111756C2/uk unknown
- 2012-11-02 SI SI201231643T patent/SI3002284T1/sl unknown
- 2012-11-02 EP EP15188086.1A patent/EP3002284B1/en active Active
- 2012-11-02 US US13/667,133 patent/US8716274B2/en not_active Ceased
- 2012-11-02 ES ES19152979T patent/ES2898938T3/es active Active
- 2012-11-02 MX MX2015003514A patent/MX361807B/es unknown
- 2012-11-02 WO PCT/US2012/063194 patent/WO2013067274A1/en active Application Filing
- 2012-11-02 TW TW106130019A patent/TWI652270B/zh active
- 2012-11-02 EP EP21171114.8A patent/EP4019508A1/en active Pending
- 2012-11-02 AU AU2012332365A patent/AU2012332365B2/en active Active
- 2012-11-02 LT LTEP15188086.1T patent/LT3002284T/lt unknown
- 2012-11-02 TW TW109129648A patent/TW202124384A/zh unknown
- 2012-11-02 RS RS20190888A patent/RS59016B1/sr unknown
- 2012-11-02 RS RS20160001A patent/RS54505B1/en unknown
- 2012-11-02 CN CN201280065965.8A patent/CN104125959B/zh active Active
- 2012-11-02 DK DK15188086.1T patent/DK3002284T3/da active
- 2012-11-02 SI SI201230367T patent/SI2773638T1/sl unknown
- 2012-11-02 PL PL15188086T patent/PL3002284T3/pl unknown
- 2012-11-02 PT PT15188086T patent/PT3002284T/pt unknown
- 2012-11-02 KR KR1020157036122A patent/KR20160003328A/ko not_active Application Discontinuation
- 2012-11-02 ES ES15188086T patent/ES2738329T3/es active Active
- 2012-11-02 AR ARP120104128A patent/AR088641A1/es active IP Right Grant
- 2012-11-02 SG SG11201401992YA patent/SG11201401992YA/en unknown
- 2012-11-02 PL PL19152979T patent/PL3521288T3/pl unknown
- 2012-11-02 EP EP22157147.4A patent/EP4050012A1/en active Pending
- 2012-11-02 DK DK12783837.3T patent/DK2773638T3/en active
- 2012-11-02 PL PL12783837T patent/PL2773638T3/pl unknown
- 2012-11-02 HU HUE12783837A patent/HUE028019T2/en unknown
- 2012-11-02 MX MX2014005331A patent/MX2014005331A/es active IP Right Grant
- 2012-11-02 IN IN3250CHN2014 patent/IN2014CN03250A/en unknown
- 2012-11-02 CN CN201710227680.4A patent/CN107011348B/zh active Active
- 2012-11-02 HU HUE15188086A patent/HUE044959T2/hu unknown
- 2012-11-02 EA EA201490858A patent/EA023263B1/ru unknown
- 2012-11-02 EP EP19152979.1A patent/EP3521288B1/en active Active
- 2012-11-02 EP EP12783837.3A patent/EP2773638B1/en active Active
- 2012-11-02 TW TW107141781A patent/TWI701250B/zh active
- 2012-11-02 KR KR1020147014661A patent/KR101659193B1/ko active IP Right Grant
- 2012-11-02 JP JP2014541114A patent/JP5976827B2/ja active Active
- 2012-11-02 PT PT127838373T patent/PT2773638E/pt unknown
- 2012-11-02 TR TR2019/09849T patent/TR201909849T4/tr unknown
- 2012-11-02 TW TW101140919A patent/TWI609868B/zh active
- 2012-11-02 ES ES12783837.3T patent/ES2555168T3/es active Active
- 2012-11-02 CA CA2853975A patent/CA2853975C/en active Active
- 2012-11-02 PE PE2014000638A patent/PE20141586A1/es active IP Right Grant
-
2014
- 2014-03-13 US US14/207,966 patent/US8921353B2/en active Active
- 2014-04-10 IL IL232060A patent/IL232060A/en active IP Right Grant
- 2014-04-28 CO CO14090476A patent/CO6950472A2/es active IP Right Grant
- 2014-04-28 CR CR20140194A patent/CR20140194A/es unknown
- 2014-04-29 CL CL2014001103A patent/CL2014001103A1/es unknown
- 2014-05-27 MA MA37075A patent/MA35819B1/fr unknown
- 2014-09-08 US US14/479,529 patent/US9238655B2/en active Active
-
2015
- 2015-02-18 HK HK15101799.4A patent/HK1201265A1/xx unknown
- 2015-08-24 JP JP2015165300A patent/JP2016028046A/ja not_active Withdrawn
- 2015-11-17 US US14/943,552 patent/US9782405B2/en active Active
- 2015-12-31 HR HRP20151442TT patent/HRP20151442T1/hr unknown
-
2016
- 2016-01-04 CY CY20161100003T patent/CY1117097T1/el unknown
- 2016-12-15 AU AU2016273930A patent/AU2016273930B2/en active Active
-
2017
- 2017-08-31 US US15/693,022 patent/US10045983B2/en active Active
-
2018
- 2018-01-04 JP JP2018000309A patent/JP6571215B2/ja active Active
- 2018-03-05 AU AU2018201557A patent/AU2018201557B2/en active Active
- 2018-06-27 US US16/020,270 patent/US20190194203A1/en not_active Abandoned
- 2018-07-16 ZA ZA2018/04727A patent/ZA201804727B/en unknown
- 2018-10-30 US US16/175,278 patent/USRE48239E1/en active Active
-
2019
- 2019-02-14 JP JP2019024668A patent/JP2019108342A/ja not_active Withdrawn
- 2019-07-18 HR HRP20191307TT patent/HRP20191307T1/hr unknown
- 2019-08-16 AU AU2019216728A patent/AU2019216728B2/en active Active
- 2019-10-31 US US16/670,898 patent/US20200062769A1/en not_active Abandoned
- 2019-12-23 AR ARP190103844A patent/AR117501A2/es unknown
-
2020
- 2020-04-22 AU AU2020202707A patent/AU2020202707B2/en active Active
- 2020-07-02 JP JP2020114594A patent/JP2020183397A/ja not_active Withdrawn
- 2020-08-24 US US17/001,205 patent/US20210079002A1/en not_active Abandoned
-
2022
- 2022-12-20 US US18/069,099 patent/US20230279012A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
DOP2015000274A (es) | Compuestos químicos | |
MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
CL2013001093A1 (es) | Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer . | |
CL2016001895A1 (es) | Compuestos | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
CL2015000530A1 (es) | Compuestos derivados ciclicos eter pirazol-4-il-heterociclil-carboxamida, como inhibidores de la quinasa pim; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, trastornos inmunologicos, enfermedades cardiovasculares, infeccion virica, inflamacion, trastornos del metabolismo/funcion endocrina y trastornos neurologicos. | |
DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
MX349004B (es) | Nuevos compuestos. | |
CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
CL2014002505A1 (es) | Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. |